Skip to main content
. 2023 May 29;53(8):704–713. doi: 10.1093/jjco/hyad044

Figure 3.

Figure 3

Subgroup analysis for progression-free survival. PFS, progression-free survival; dNLR, derived neutrophil–lymphocyte ratio; GPS, Glasgow Prognostic Score; CRP, C-reactive protein; Alb, albumin; HR, hazard ratio; iCT, induction chemotherapy using gemcitabine; CRT, S-1 concurrent radiotherapy.